Psoriasiform exfoliative erythroderma induced by golimumab
Summary Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, th...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental dermatology 2014-10, Vol.39 (7), p.813-815 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 815 |
|---|---|
| container_issue | 7 |
| container_start_page | 813 |
| container_title | Clinical and experimental dermatology |
| container_volume | 39 |
| creator | Mateo, S. García-Martínez, F. J. Sánchez-Aguilar, D. Amarelo, J. Toribio, J. |
| description | Summary
Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described. |
| doi_str_mv | 10.1111/ced.12402 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1561971421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3429621171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4612-2ba6c6a0fccbbeceb24bf72cfaa3e1094c79af311d5fab52a1f9ac9af3e9dbce3</originalsourceid><addsrcrecordid>eNp10MlOwzAQBmALgaAsB14AReICh4DHzkK4QVkKQoAQm7hYtjMGl6QBuwH69rgt5YCEL5ZG3_z2DCHrQHcgnF2N5Q6whLI50gGepTFjnM6TDuU0j7OC7y2RZe_7lAKHPF0kSyyFNOMJdMj-tW-cld6axtURfpmmsnJoPzBCNxq-uKZEV8vIDso2vBKpUfQcRN3WUq2SBSMrj2s_9wq5Ozm-7fbii6vTs-7BRayTDFjMlMx0JqnRWinUqFiiTM60kZIj0CLReSENByhTI1XKJJhC6nEJi1Jp5Ctka5r75pr3Fv1Q1NZrrCo5wKb1IowCRQ4Jg0A3_9B-07pB-N1EJbTYy1hQ21OlXeO9QyPenK2lGwmgYrxQEUYVk4UGu_GT2Ko6VGdytsEAdqfg01Y4-j9JdI-PZpHxtMP6IX79dkj3KrKc56l4uDwVvZvD8_PHp3uR8G_zcI-I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1561409862</pqid></control><display><type>article</type><title>Psoriasiform exfoliative erythroderma induced by golimumab</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Mateo, S. ; García-Martínez, F. J. ; Sánchez-Aguilar, D. ; Amarelo, J. ; Toribio, J.</creator><creatorcontrib>Mateo, S. ; García-Martínez, F. J. ; Sánchez-Aguilar, D. ; Amarelo, J. ; Toribio, J.</creatorcontrib><description>Summary
Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1111/ced.12402</identifier><identifier>PMID: 25156341</identifier><identifier>CODEN: CEDEDE</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Antibodies, Monoclonal - adverse effects ; Dermatitis, Exfoliative - chemically induced ; Humans ; Male ; Middle Aged ; Pharmaceutical industry ; Psoriasis ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Clinical and experimental dermatology, 2014-10, Vol.39 (7), p.813-815</ispartof><rights>2014 British Association of Dermatologists</rights><rights>2014 British Association of Dermatologists.</rights><rights>Copyright © 2014 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4612-2ba6c6a0fccbbeceb24bf72cfaa3e1094c79af311d5fab52a1f9ac9af3e9dbce3</citedby><cites>FETCH-LOGICAL-c4612-2ba6c6a0fccbbeceb24bf72cfaa3e1094c79af311d5fab52a1f9ac9af3e9dbce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25156341$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mateo, S.</creatorcontrib><creatorcontrib>García-Martínez, F. J.</creatorcontrib><creatorcontrib>Sánchez-Aguilar, D.</creatorcontrib><creatorcontrib>Amarelo, J.</creatorcontrib><creatorcontrib>Toribio, J.</creatorcontrib><title>Psoriasiform exfoliative erythroderma induced by golimumab</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>Summary
Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.</description><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Dermatitis, Exfoliative - chemically induced</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Pharmaceutical industry</subject><subject>Psoriasis</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MlOwzAQBmALgaAsB14AReICh4DHzkK4QVkKQoAQm7hYtjMGl6QBuwH69rgt5YCEL5ZG3_z2DCHrQHcgnF2N5Q6whLI50gGepTFjnM6TDuU0j7OC7y2RZe_7lAKHPF0kSyyFNOMJdMj-tW-cld6axtURfpmmsnJoPzBCNxq-uKZEV8vIDso2vBKpUfQcRN3WUq2SBSMrj2s_9wq5Ozm-7fbii6vTs-7BRayTDFjMlMx0JqnRWinUqFiiTM60kZIj0CLReSENByhTI1XKJJhC6nEJi1Jp5Ctka5r75pr3Fv1Q1NZrrCo5wKb1IowCRQ4Jg0A3_9B-07pB-N1EJbTYy1hQ21OlXeO9QyPenK2lGwmgYrxQEUYVk4UGu_GT2Ko6VGdytsEAdqfg01Y4-j9JdI-PZpHxtMP6IX79dkj3KrKc56l4uDwVvZvD8_PHp3uR8G_zcI-I</recordid><startdate>201410</startdate><enddate>201410</enddate><creator>Mateo, S.</creator><creator>García-Martínez, F. J.</creator><creator>Sánchez-Aguilar, D.</creator><creator>Amarelo, J.</creator><creator>Toribio, J.</creator><general>Blackwell Publishing Ltd</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201410</creationdate><title>Psoriasiform exfoliative erythroderma induced by golimumab</title><author>Mateo, S. ; García-Martínez, F. J. ; Sánchez-Aguilar, D. ; Amarelo, J. ; Toribio, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4612-2ba6c6a0fccbbeceb24bf72cfaa3e1094c79af311d5fab52a1f9ac9af3e9dbce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Dermatitis, Exfoliative - chemically induced</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Pharmaceutical industry</topic><topic>Psoriasis</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mateo, S.</creatorcontrib><creatorcontrib>García-Martínez, F. J.</creatorcontrib><creatorcontrib>Sánchez-Aguilar, D.</creatorcontrib><creatorcontrib>Amarelo, J.</creatorcontrib><creatorcontrib>Toribio, J.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mateo, S.</au><au>García-Martínez, F. J.</au><au>Sánchez-Aguilar, D.</au><au>Amarelo, J.</au><au>Toribio, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriasiform exfoliative erythroderma induced by golimumab</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2014-10</date><risdate>2014</risdate><volume>39</volume><issue>7</issue><spage>813</spage><epage>815</epage><pages>813-815</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><coden>CEDEDE</coden><abstract>Summary
Golimumab is a fully human anti‐tumour necrosis factor (TNF)‐α monoclonal antibody approved for use in the treatment of active rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Psoriasis induced by treatment with anti‐TNF drugs is well documented, but to our knowledge, the development of clinical features of psoriasiform exfoliative erythroderma during treatment with golimumab has not been previously described.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>25156341</pmid><doi>10.1111/ced.12402</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-6938 |
| ispartof | Clinical and experimental dermatology, 2014-10, Vol.39 (7), p.813-815 |
| issn | 0307-6938 1365-2230 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1561971421 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal - adverse effects Dermatitis, Exfoliative - chemically induced Humans Male Middle Aged Pharmaceutical industry Psoriasis Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Psoriasiform exfoliative erythroderma induced by golimumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T05%3A57%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriasiform%20exfoliative%20erythroderma%20induced%20by%20golimumab&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Mateo,%20S.&rft.date=2014-10&rft.volume=39&rft.issue=7&rft.spage=813&rft.epage=815&rft.pages=813-815&rft.issn=0307-6938&rft.eissn=1365-2230&rft.coden=CEDEDE&rft_id=info:doi/10.1111/ced.12402&rft_dat=%3Cproquest_cross%3E3429621171%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1561409862&rft_id=info:pmid/25156341&rfr_iscdi=true |